BioWorld

Oct. 28, 2002

View Archived Issues

MedImmune Expects To Take FluMist Back To Panel This Year

An FDA advisory panel later this year is expected to vote on whether FluMist should enter the market as a nasal influenza vaccine for patients who are ages 19 months to 64 years old. (BioWorld Today) Read More

NPS Prices $95.8M Offering From Shelf For Phase III Trials

Read More

Rats' Antennae-Like Whiskers Perform Mental Arithmetic, By Neuronal Spectral Mixing

Read More

Harvard Bioscience Completes Genomics Solutions Acquisition

Read More

Epimmune To Test Public Waters With $9.6M Offering

Read More

Other News To Note

Read More